Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.33    
    

 
  SUBSCRIPTION AGREEMENT    
    

Date                        

To the Holders whose

names and addresses are set

forth on Schedule 1 hereto

Ladies
and Gentlemen: 

        This
letter (the "Agreement") is being written for the purpose of setting forth the terms of the understandings between  ev3 Endovascular, Inc., a Delaware
corporation (the "Company"), and each of the holders listed on  Schedule 1 hereto (each a "Holder" and,
collectively, the
"Holders") in connection with the sale and purchase of the Notes (as defined below) of the Company. 

        If
you are in agreement with the terms and conditions set forth herein, please sign the last page of one copy of this letter and return it to us, whereupon this letter shall represent a
legally binding agreement between us and shall supersede any prior agreement between you and the Company or any third party regarding the sale and purchase of the Notes. Please keep the other copy of
this letter for your files. 

        1.    AUTHORIZATION OF PROMISSORY NOTES.    The Company has authorized the creation, issuance and sale
[    ] demand promissory notes to the Holders, as described in Section 2 hereof and in substantially the forms set forth and attached hereto as  Exhibit A, the aggregate
principal amount of such notes being equal to US$[            ].
 

        2.    SALE AND PURCHASE OF PROMISSORY NOTES.    Subject to the terms and conditions hereof and in reliance upon the
Company's and the Holders' respective representations and warranties set forth below, the Company agrees to sell to each Holder, and each of the Holders severally agrees to purchase from the Company
in accordance with the terms of this Agreement one (1) demand promissory note, in the respective principal amount set forth opposite such Holder's name on  Schedule 1hereto (each a
"Note" and collectively, the
"Notes"). The Company's agreement with each Holder is a separate agreement, and the sale of each Note to each Holder is a separate sale. 

        3.    CLOSING.    

        (a)    Time and Place.    The closing of the purchase of the Notes described herein shall take place at the offices of
[                        ], at [            ] Minneapolis time, on or
about [                        ], or at such other place or different
time or day as may be mutually acceptable to the Holders and the Company (the "Closing"). The date and time on which the Closing occurs shall be
referred to as the "Closing Date." 

        (b)    Closing.    Subject to the terms and conditions hereof, on the Closing Date, the Company shall sell to each
Holder, and each Holder shall purchase from the Company, one (1) Note in the respective principal amount set forth opposite such Holder's name on  Schedule 1 hereto. 

        (c)    Payment and Tender.    On the Closing Date, each Holder shall pay to the Company that amount equaling such
Holder's aggregate purchase commitment as set forth opposite such Holder's 

 

name
on Schedule 1 hereto, by wire transfer or bank or cashier's check payable to the Company, or any combination thereof. 

        (d)    Delivery of Promissory Notes.    On the Closing Date, the Company shall deliver to each Holder its respective
Note, duly executed by the Company, in favor of such Holder, and representing such
Holder's right to receive payment of the principal amount of such Note and all accrued and unpaid interest thereon. 

        4.    USE OF PROCEEDS.    The proceeds to the Company from the issuance and sale of the Notes under this Agreement
will be used by the Company for general working capital purposes. 

        5.    WARRANTIES AND REPRESENTATIONS OF THE COMPANY.    To induce each of the Holders to enter into this Agreement and
to purchase its respective Note in the principal amount set forth opposite such Holder's name on Schedule 1hereto, the Company hereby represents
and warrants to each Holder that, except as set forth on the correspondingly numbered disclosure schedules attached hereto, as of the Closing Date: 

        (a)    Organization and Standing.    The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and in all other jurisdictions where the failure to qualify as a foreign corporation would have a Material Adverse Effect, and has the corporate power
and authority to conduct its business as it is presently conducted. 

        (b)    Governing Instruments.    The Company has provided legal counsel for the Holders with true and complete copies
of the duly and legally adopted Amended and Restated Certificate of Incorporation and Bylaws of the Company, as amended through the date hereof (collectively, the
"Organizational Documents"). 

        (c)    Subsidiaries, Etc.    The Company does not have any ownership interest, direct or indirect, controlling or
otherwise, in any corporation, partnership, joint venture, association or other business enterprise. 

        (d)    Capitalization.    The authorized capital stock of the Company consists of 100 shares of Common Stock, all of
which are issued and outstanding. All issued and outstanding shares of the Company's capital stock have been duly authorized and validly issued, are fully paid and non-assessable. There
are no outstanding rights of first refusal, preemptive rights or other rights, options, warrants, conversion rights, or other agreements either directly or indirectly for the purchase or acquisition
from the Company of any shares of its capital stock. All of the outstanding shares of capital stock of the Company have been duly and validly issued in compliance with federal and state securities
laws, or exemptions thereunder. All of the outstanding shares of capital stock of the Company are owned by ev3 LLC, a Delaware limited liability company (the
"Parent"). 

        (e)    Authorization.    All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement, the performance of all the Company's obligations hereunder, and for the authorization, issuance, sale and delivery of the
Notes has been taken and no further action is required. This Agreement, when executed and delivered, shall constitute a valid and legally binding obligation of the Company enforceable in
accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors. 

2

 

        (f)    Validity of Notes.    The issuance and sale of the Notes are not and will not be subject to any preemptive
rights or rights of first refusal and, when issued, sold and delivered in accordance with the provisions of this Agreement, the Notes will be validly issued and fully paid; provided, however, that
such Notes may be subject to restrictions on transfer under the terms of such Notes or state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time a
transfer is proposed. 

        (g)    Registration Rights and Voting Rights.    The Company is not under any obligation to register any of its
presently outstanding securities or any of its securities which may hereafter be issued, and, to the Company's knowledge, no stockholder of the Company has entered into any stockholder or voting
agreement with respect to the voting of any of the capital stock of the Company. 

        (h)    Consents.    No consent, approval, order, or authorization of, or registration, qualification, designation,
declaration, or filing with, any corporation, person or firm or any public, governmental or judicial authority, is required on the part of the Company in connection with the execution and delivery of
this Agreement, the creation, issuance or sale of the Notes, or the consummation of any other transaction contemplated hereby, except as such as have been duly obtained or made, as the case may be,
and are in full force and effect and except for notices required or permitted to be filed after the Closing Date, which notices, if any, will be filed by the Company on a timely basis. 

        (i)    Patents and Trademarks.    To the Company's knowledge, the Company owns or possesses sufficient legal rights to
all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted, without
any known infringement of the rights of others. There are no outstanding options, licenses or agreements of any kind relating to the foregoing, nor is the Company bound by or a party to any options,
licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of
any other person or entity other than such licenses or agreements arising from the purchase of "off the shelf" or standard products. The Company has not received any communications alleging that the
Company has violated or, by conducting its business as proposed, would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses or other proprietary
rights of any other person or entity. The Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other
agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with their duties to the Company or that would conflict with the Company's business
as proposed to be conducted. Neither the execution nor delivery of this Agreement, nor the carrying on of the Company's business by the employees of the Company, nor the conduct of the Company's
business as proposed, will, to the Company's knowledge, conflict with or result in a breach of the terms, conditions or
provisions of, or constitute a default under, any contract, covenant or instrument under which any employee is now obligated. To the Company's knowledge, the Company is not and will not be required to
utilize any patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights that have been assigned to the Company. 

        (j)    Financial Statements.    The Company has delivered to the Holders an unaudited balance sheet dated as of
[                        ], and an income statement for the twelve-month period ending
[                        ] (the "Financial
Statements"). The Company has also delivered to the Holders an unaudited balance sheet dated
[                        ], and an income statement for the
one-month and eleven-month periods ending [                        ] (the "Interim
Statements"). The Financial Statements and
the Interim Statements, prepared in accordance with generally accepted accounting principles ("GAAP") consistently applied, 

3

 

fairly
and correctly disclose the financial condition of the Company as of the dates and during the periods indicated therein, subject to normal year-end adjustments and the absence of all
footnotes required by GAAP. 

        (k)    Tax Returns and Payments.    All taxes shown to be due and payable on the Company's returns, any assessments
imposed, and to the Company's knowledge all other taxes due and payable by the Company on or before the Closing Date have been paid or will be paid. The Company has not been advised (i) that
any of its returns, federal, state or other, have been or are being audited as of the date hereof, or (ii) of any deficiency in assessment or proposed judgment to its federal, state or other
taxes. The Company has no knowledge of any liability of any tax to be imposed upon its properties or assets as of the Closing Date that is not adequately provided for. 

        (l)    Environmental, Safety and Other Laws.    The Company is not in material violation of any applicable statute,
law or regulation to which it is subject including, without limitation, those relating to the environment or occupational health and safety, and no material expenditures are or will be required in
order to comply with any such existing statute, law or regulation. 

        (m)    Compliance with Other Instruments.    The Company is not, and will not by virtue of entering into and
performing this Agreement and the transactions contemplated hereby be, in violation of any term of its Organizational Documents. The Company is not, and will not by virtue of entering into and
performing this Agreement and the transactions contemplated hereby be, (i) in violation with any terms or provisions of any material mortgage, indenture, contract, agreement, instrument,
judgment or decree to which it is a party or by which it is bound, (ii) in violation of any order addressed specifically to the Company, or (iii) in violation with any material statute,
rule or regulation applicable to the Company,
other than such violations of any of the foregoing, with respect to (i) and (iii), that do not, either individually or in the aggregate, have a Material Adverse Effect. 

        (n)    Litigation.    There are no proceedings or actions pending that limit or impair any of the Company's powers,
rights and privileges to enter into this Agreement or to consummate the transactions contemplated hereby. There is no action or proceeding against, or initiated by the Company which is currently
pending or which the Company currently intends to initiate. To the Company's knowledge, there are no actions or proceedings against the Parent which relate to the operations of the Company. 

        (o)    Full Disclosure.    The Company has provided each Holder with all the information such Holder has requested for
deciding whether to purchase its respective Note. This Agreement and the other written information provided to each Holder by the Company, when taken as a whole, do not contain any untrue statement of
a material fact or omit a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. 

        (p)    Material Contracts.    Schedule 5(p) hereto contains a detailed list of the Company's material
contracts, agreements, instruments, commitments and other arrangements to which the Company is a party or otherwise relating to or affecting any of its assets, including without limitation,
employment, severance or consulting agreements; loan, credit or security agreements; joint venture agreements and distribution agreements (each a
"Contract"). Each such Contract is valid, binding and enforceable against the Company and, to the Company's best knowledge, the other parties thereto,
in accordance with its terms, and in full force and effect on the date hereof. 

4

 

        (q)    Absence of Undisclosed Liabilities.    To the Company's best knowledge, it does not have any debt, obligation
or liability (whether accrued, absolute, contingent, liquidated or otherwise, whether due or to become due), arising out of any act or omission at or prior to the Closing Date, or any state of facts
existing at or prior to the Closing Date, including taxes with respect to or based upon the transactions or events occurring at or prior to the Closing Date, except current liabilities incurred and
obligations under agreements entered into, in the usual and ordinary course of business, none of which (individually or in the aggregate) could have a Material Adverse Effect. 

        6.    WARRANTIES AND REPRESENTATIONS OF THE HOLDERS.    Each of the Holders severally represents and warrants to the
Company that with respect to such Holder: 

        (a)    Information About the Company.    The Holder has obtained all information about the Company as such Holder
believes relevant to its decision to purchase its respective Note. The Holder has also had the
opportunity to ask questions of, and to receive answers from, the Company, its officers and directors, or other agents or representatives of the Company concerning the terms and conditions of such
purchase and the business and affairs of the Company and to obtain any additional information necessary to verify such information, and the Holder has received such information concerning the Company
as such Holder considers necessary or advisable in order to form a decision concerning its purchase of its respective Note from the Company. 

        (b)    Forward-Looking Information.    The Holder acknowledges and understands that any information provided about the
Company's future plans and prospects is uncertain and subject to all of the uncertainties inherent in the future predictions. 

        (c)    No Review by Federal or State Regulators.    The Holder understands that this transaction has not been
scrutinized by the United States Securities and Exchange Commission (the "Commission") or by any state securities or other authority and, because of the
small number of persons solicited to participate in the sale and purchase of the Notes and the private nature of the transaction, that all documents, records, and books pertaining to this investment
have been made available to the Holder and the Holder's representatives, such as attorneys, accountants and/or purchaser representatives. 

        (d)    High Degree of Risk.    The Holder realizes that its respective purchase hereunder involves a high degree of
risk, including the risk of loss of all amounts owed to it under the terms of its respective Note. 

        (e)    Ability to Bear the Risk.    The Holder is able to bear the economic risk of its purchase of its respective
Note, including the total loss of all principal amounts loaned to the Company under the terms of its respective Note. 

        (f)    Financial Condition.    The Holder's current financial condition is such that (and the Holder expects its
financial condition to be such that in the near future) the Holder does not have any present or contemplated need to dispose of any part of its respective Note to satisfy any existing or contemplated
undertaking, need or indebtedness. 

        (g)    Business Sophistication.    The Holder is experienced and knowledgeable in financial and business matters and
the Holder is capable of evaluating the merits and risks of the prospective purchase of its respective Note. 

        (h)    Residency.    The state in which the Holder's principal office is located is the state 

5

 

set
forth in such Holder's address on Schedule 1 hereto. 

        (i)    No General Solicitation.    The Holder's purchase of its respective Note is not the result of any general
solicitation or general advertising, including, but not limited to (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or
broadcast over television or radio; and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising. 

        (j)    Legal Representation.    The Holder understands that: (i) the Company has engaged legal counsel to
represent the Company in connection with the creation and sale of the Notes as contemplated herein; (ii) legal counsel engaged by the Company does not represent the Holder or the Holder's
interests; and (iii) the Holder is not relying on legal counsel engaged by the Company. The Holder has had the opportunity to engage, and obtain advice from, Holder's own legal counsel with
respect to the investment contemplated herein. 

        (k)    Accredited Status.    The Holder is an "Accredited Investor" as defined in Rule 501(a) of
Regulation D under the Securities Act of 1933, as amended (the "Act"). 

        (l)    Investment Purpose in Purchasing the Notes.    The Holder acknowledges that the Notes have not been registered
under the Act or applicable state securities laws and that the Notes will be sold to the Holders in reliance on exemptions from the registration requirements of the Act and applicable state securities
laws and in reliance on the Holders' and the Company's respective representations and agreements contained herein. The Holder is subscribing to purchase its respective Note for the account of such
Holder for investment purposes only and not with a view to resale or distribution. The Holder has no present intention to divide its participation with others or to resell or otherwise dispose of all
or any portion of its respective Note purchased by it hereunder, but subject, nevertheless, to any requirement of law that the disposition of the Holder's property shall at all times be within the
Holder's control, and without prejudice to the Holder's right at all times to sell or otherwise dispose of all or any portion of such Holder's Note under a registration under the Act or under an
exemption from said registration available under the Act. In making these representations, the Holder understands that, in the view of the Commission, exemption of such Holder's respective Note from
the registration requirements of the Act would not be available if, notwithstanding the representations of the Holder, the Holder has in mind merely purchasing its respective Note for resale upon the
occurrence or non-occurrence of some predetermined event. 

        (m)    Compliance with Transfer Restrictions.    The Holder agrees that if its respective Note, or any portion of it,
is sold or otherwise transferred in the future, the Holder shall sell or otherwise transfer the same
pursuant to the terms of this Agreement, the Holder's Note, the requirements of the Act and applicable state securities laws. Further, the Holder agrees that it will not transfer any portion of its
respective Note unless (i) the Holder has provided the Company with written notice of any proposed disposition prior to the transfer, and (ii) with respect to any proposed transfer to
any Person which is not an affiliate of either Warburg Pincus & Co. or the Vertical Group, L.P., the Holder shall provide or obtain (a) a reasonably detailed statement of the
circumstances surrounding such proposed transfer, (b) the written consent of the Company to the transfer, and (c) an opinion of counsel reasonably satisfactory in form and substance to
the Company to the effect that such transfer is exempt from the registration requirements under the Act and applicable state securities laws or there is then in effect a registration statement under
the Act then covering such proposed disposition. 

        (n)    Restrictive Legend.    The Holder agrees that the Company may place one or more 

6

 

restrictive
legends on any Note, containing substantially the following language: 

THIS
NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), HAS NOT BEEN REGISTERED UNDER ANY STATE SECURITIES LAW, AND IS SUBJECT TO A SUBSCRIPTION AGREEMENT DATED
[                        ], AMONG EV3 INC. AND CERTAIN PERSONS PARTY THERETO. THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, OR
TRANSFERRED UNLESS (i) THERE IS AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT GOVERNING SUCH SECURITIES, (ii) SUCH SALE OR TRANSFER IS MADE TO AN AFFILIATE OF THE TRANSFEROR OR OTHER PERMITTED TRANSFEREE, OR (iii) THE COMPANY
RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER REASONABLY SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE ACT, AND UNDER THE APPLICABLE STATE SECURITIES
LAWS. 

        7.    COVENANTS.    Each of the Parties hereto shall execute such documents and other papers and take such further
actions as may be reasonably required or desirable to carry out the provisions hereof and the transactions contemplated hereby. 

        8.    CONDITIONS TO CLOSING.    The obligation of each Holder to purchase and pay for its respective Note on the
Closing Date is subject to the fulfillment, or waiver by such Holder prior to or on the Closing Date, of the conditions set forth in this Section 8. 

        (a)    Transaction Documents.    This Agreement and each of the other instruments and agreements contemplated hereby
shall have been duly executed and delivered by the parties thereto and such agreements shall be in full force and effect. 

        (b)    Injunction.    There shall be no effective injunction, writ, preliminary restraining order or any order of any
nature issued by a court of competent jurisdiction directing that the transactions provided for herein or any of them not be consummated as herein provided. 

        (c)    Blue Sky.    The Company shall have obtained all necessary Blue Sky law and other permits and qualifications,
or have the availability of exemptions therefrom, required by any state for the offer and sale of the Notes. 

        (d)    Opinion.    The Company shall have furnished each Holder the opinion of
[                                    ], counsel to the Company, dated
as of the Closing Date, substantially in the form attached as Exhibit B
hereto. 

        9.    INTERPRETATION OF THIS AGREEMENT.    

        (a)    Terms Defined.    As used in this Agreement, the following terms have the respective meaning set forth below: 

        Material Adverse Effect:    a material adverse effect on the business, properties, assets, liabilities, prospects, profits,
results of operations or condition (financial or otherwise) of the Company, and its subsidiaries, taken as a whole. 

        Person:    an individual, partnership, joint-stock company, corporation, limited 

7

 

liability
company, trust or unincorporated organization, and a government or agency or political subdivision thereof. 

        (b)    Directly or Indirectly.    Where any provision in this Agreement refers to action to be taken by any Person, or
which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly by such Person. 

        (c)    Governing Law.    This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware applicable to contracts made and to be performed entirely within such State. 

        (d)    Section Headings.    The headings of the sections and subsections of this Agreement are inserted for
convenience only and shall not be deemed to constitute a part hereof. 

        10.    MISCELLANEOUS.    

        (a)    Notices.    All communications under this Agreement shall be in writing and shall be delivered by hand or
facsimile or mailed by overnight courier or by registered mail or certified mail, postage prepaid: 

          (i)  if
to the Company, 4600 Nathan Lane North, Plymouth, MN 55442-2920 (facsimile: (763) 398-7240 Legal Dept.), marked for the attention of
Jim Corbett, or at such other address or facsimile number as the Company may have furnished the other Parties hereto in writing; 

         (ii)  if
to any Holder, at the address or facsimile number set forth below such Holder's name on Schedule 1 hereto, or
at such other address or facsimile number as the Holder may have furnished the other Parties hereto in writing. 

        (b)    Delivery of Notices.    Any notice so addressed shall be deemed to be given: if delivered by hand or facsimile,
on the date of such delivery, if a business day, otherwise the first business day thereafter; if mailed by courier, on the first business day following the date of such mailing; and if mailed by
registered or certified mail, on the third business day after the date of such mailing. 

        (c)    Expenses and Taxes.    

          (i)  The
Company agrees to pay all reasonable fees and expenses incurred by the Holders in connection with the creation, execution and delivery of this Agreement and the
Notes. 

         (ii)  The
Company will pay, and save and hold the Holders harmless from any and all liabilities (including interest and penalties) with respect to, or resulting from any
delay or failure in paying, stamp and other taxes (other than income taxes), if any, which may be payable or determined to be payable on the execution and delivery of this Agreement or purchase of the
Notes. 

        (d)    Reproduction of Documents.    This Agreement and all documents relating thereto, including, without limitation,
(i) consents, waivers and modifications relating hereto which may hereafter be executed and (ii) financial statements, certificates and other information previously or hereafter
furnished to a Holder, may be reproduced by such Holder by any photographic, photostatic, microfilm, 

8

 

micro-card,
miniature photographic or other similar process and such Holder may destroy any original document so reproduced. All Parties hereto agree and stipulate that any such
reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether or not such reproduction was
made by such Holder in the regular course of business) and that any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence. 

        (e)    Survival.    All warranties, representations, and covenants made by a Holder and the Company herein or in any
certificate or other instrument delivered by a Holder or the Company under this Agreement shall be considered to have been relied upon by the Company or such Holder, as the case may be, and shall
survive any delivery to such Holder of its respective Note, or payment to the Company for such Note, regardless of any investigation made by the Company or such Holder, as the case may be, or on the
Company's or such Holder's behalf. All statements in any such certificate or other instrument shall constitute warranties and representations by the Company hereunder. 

        (f)    Successors and Assigns; No Third Party Beneficiaries.    This Agreement shall inure to the benefit of and be
binding upon the successors and assigns of each of the Parties. Nothing in this Agreement shall confer upon any Person not a party to this Agreement any rights or remedies of any nature or kind
whatsoever under or by reason of this Agreement. 

        (g)    Entire Agreement; Amendment and Waiver.    This Agreement, and the Exhibits and Schedules hereto, constitute
the entire understanding of the Parties hereto and supersede all prior agreements or understandings with respect to the subject matter hereof among such parties. This Agreement may be amended, and the
observance of any term of this Agreement may be waived upon the prior written consent of the Company and each Holder. 

        (h)    Severability.    In the event that any part or parts of this Agreement shall be held illegal or unenforceable
by any court or administrative body of competent jurisdiction, such determination shall not affect the remaining provisions of this Agreement which shall remain in full force and effect. 

        (i)    Obligations Several.    Notwithstanding anything to the contrary contained in this Agreement, each of the
Holders' representations and warranties, covenants and other agreements under this Agreement shall be several, but not joint. 

        (j)    Limitation on Enforcement of Remedies.    The Company hereby agrees that it will not assert against the limited
partners of any Holder any claim it may have under this Agreement by reason of any failure or alleged failure by any Holder to meet its obligations hereunder. 

        (k)    Counterparts.    This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original and all of which together shall be considered one and the same agreement. 

        [Remainder of Page Left Blank Intentionally]

9

        IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the day and year first above written. 

	
ev3 ENDOVASCULAR, INC.	
 	

 	

 	

 
	

 	

 	
 	

 	

 	

 
	By:	    
 Name:

Title:	 	 	 	 
	

 	

 	
 	

ACCEPTED AND APPROVED

AS OF THE DAY AND YEAR

FIRST SET FORTH ABOVE
	

 	

 	
 	

VERTICAL FUND I, L.P.
	

 	

 	
 	

By:	

Vertical Group, L.P., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:
	

 	

 	
 	

 	

 	

 
	 	 	 	VERTICAL FUND II, L.P.
	

 	

 	
 	

By:	

Vertical Group, L.P., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:

[Signature Page to Subscription Agreement]

	 	 	 	ACCEPTED AND APPROVED

AS OF THE DAY AND YEAR

FIRST SET FORTH ABOVE
	

 	

 	
 	

WARBURG, PINCUS EQUITY PARTNERS, L.P.
	

 	

 	
 	

By:	

Warburg Pincus & Co., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:
	

 	

 	
 	

 	

 	

 
	 	WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS I, C.V.
	

 	

 	
 	

By:	

Warburg Pincus & Co., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:
	

 	

 	
 	

 	

 	

 
	 	WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS II, C.V.
	

 	

 	
 	

By:	

Warburg Pincus & Co., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:
	

 	

 	
 	

 	

 	

 
	 	WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS III, C.V.
	

 	

 	
 	

By:	

Warburg Pincus & Co., its General Partner
	

 	

 	
 	

 	

 	

 
	 	 	 	 	By:	    
 Name:

Title:

QuickLinks

Exhibit 10.33

SUBSCRIPTION AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.34    
    

 
 

DISTRIBUTION AGREEMENT    
    

between

INVATEC
S.r.l. (hereinafter referred to as "INVATEC") having a registered office at Via Martiri della Libertà 7, Roncadelle (BS), Italy,
represented by its Chief Executive Officer, Mr. Andrea Venturelli, 

and 

ev3 Inc.
(hereinafter referred to as "EV3") having registered office at 4600 Nathan Lane, Plymouth Minnesota 55442, represented by its President and Chief Executive Officer,
Mr. James M. Corbett, 

(INVATEC and EV3 are hereinafter also referred to as the "PARTIES") 

WITNESSETH

        WHEREAS,
INVATEC operates in the business of designing, developing, manufacturing and selling under the  TRADEMARK and/or trade name "INVATEC" the PRODUCTS (as hereinafter defined); 

        WHEREAS,
EV3 is willing to act as INVATEC's exclusive distributor in the TERRITORY (as
hereinafter defined) as to the PRODUCTS, upon the terms and conditions set forth in this AGREEMENT; 

        NOW,
THEREFORE, the PARTIES hereto agree as follows: 

ARTICLE 1. DEFINITIONS.  

        As used in this AGREEMENT the following words will have the meaning defined hereunder (plural shall include
singular and vice versa): 

        1.1    "AGREEMENT" shall mean: this DISTRIBUTION AGREEMENT; 

        1.2    "AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES" shall mean: the aggregate minimum value of orders of the  PRODUCTS which EV3 must place during any twelve (12) months period for
delivery in the same twelve (12) months period, starting from the  FIRST APPROVAL DATE;
 

        1.3    "AFFILIATE": means any entity that, directly or indirectly, now or hereafter controls or is controlled by or is under
common control of a PARTY hereto, except that in countries where ownership of a majority or controlling interest by a foreign entity is not permitted by
law, rule or regulations, the parent's direct or indirect voting interest may be less than a majority or controlling interest. ("Control"—including the terms "controls", "controlled by",
"controlling" and "under common control with"—are understood as meaning the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of
a person or entity whether through the ownership of voting security, by contract or otherwise); 

 

        1.4    "ANNUAL TARGETS" shall mean: the targeted orders per each group of  PRODUCTS during any twelve (12) months period for delivery in the same twelve (12) months period for EV3
to reach, starting from the  FIRST APPROVAL DATE; 

        1.5    "CLINICAL TEST" shall mean: any clinical trial, test and/or whatsoever analysis which is required by the Laws, necessary
and/or useful for obtaining from FDA and/or any further competent authority of the TERRITORY the approval to the placement on the market and the  REGISTRATION of the
PRODUCTS in the TERRITORY; 

        1.6    "EFFECTIVE DATE" shall mean: the date of signature of the AGREEMENT by
the latter PARTY hereto; 

        1.7    "FDA" shall mean: the United States Food and Drug Administration; 

        1.8    "FIRST APPROVAL DATE" shall have the meaning set forth by Article 6.3; 

        1.9    "FORCE MAJEURE" shall have the meaning set forth by Article 15; 

        1.10    "GROSS MARGIN" shall mean: the difference between, the aggregate amount paid by EV3 to  INVATEC for purchasing the PRODUCTSand the manufacturing
costs incurred into by  INVATEC for the PRODUCTS sold to EV3, during any contractual year; 

        1.11    "GROSS PROFIT" shall mean: the difference between the aggregate net amounts invoiced by EV3 to its customers on the
sales of the PRODUCTS and the aggregate net amounts charged by INVATEC to EV3 for the sale of the  PRODUCTS; 

        1.12    "INFORMATION" shall mean: any data relating to the PRODUCTS; 

        1.13    "INITIAL TERM" shall have the meaning set forth by Article 11.1; 

        1.14    "LAWS" shall mean: all the laws, regulations, ordinances and similar legally enforceable requirements applicable in the  TERRITORY; 

        1.15    "LOSSES" shall have the meaning set forth by Article 8.2; 

        1.16    "MINIMUM ANNUAL VOLUME OF PURCHASES" shall mean: the minimum volume of orders per each group of  PRODUCTS that EV3 must place during any twelve (12) months period for delivery in
the same twelve (12) months period, starting from the  FIRST APPROVAL DATE; 

        1.17    "MINIMUM EV3 STAFF" shall have the meaning set forth by Article 6.5; 

        1.18    "OVERLAPPING PRODUCTS" shall mean: PRODUCTS manufactured by  INVATEC which are similar to those PRODUCTS
which are already manufactured and/or sold also by EV3 under
its own brand name at the effective date of this Distribution AGREEMENT; 

        1.19    "PARTIES" shall mean: INVATEC and EV3; 

        1.20    "PRICE-LIST" shall have the meaning set forth by Article 5.6; 

2

 

        1.21    "PRODUCT" shall mean: any endovascular and cardiology device manufactured by  INVATEC, with the sole exclusion of OEM PRODUCTS. The 
PARTIES expressly agree that this AGREEMENT is to be considered automatically extended to any new
cardiology and endovascular device which INVATEC may design, develop and launch after the Effective Date. The list of the  PRODUCTS currently manufactured by INVATEC is shown in Exhibit 1; 

        1.22    "REGISTRATION" shall mean: the necessary authorizations for placement on the market, marketing, distribution and sale in
the TERRITORY of the PRODUCTS granted by any competent authorities of the  TERRITORY, including, without limitation, the FDA;

        1.23    "RENEWED TERM" shall mean: both the FIRST RENEWED TERM and any
Successive RENEWED TERMS of expiration of the AGREEMENT in case of renewal pursuant to
Article 11.1; 

        1.24    "ROLLING FORECAST" shall have the meaning set forth by Article 12.2; 

        1.25    "SIGN UP FEE" shall have the meaning set forth by Article 2.5; 

        1.26    "SPECIFICATION" shall have the meaning set forth by Article 7.1; 

        1.27    "TERM" shall mean: the time period commencing on the Effective Date and expiring on the date of expiration or
termination as provided for in the AGREEMENT; 

        1.28    "TERRITORY" shall mean: the TERRITORY of the United States of America
and Puerto Rico; 

        1.29    "TRADEMARKS" shall mean: all INVATEC's proprietary  TRADEMARKS to be used for the REGISTRATIONS.

ARTICLE 1. APPOINTMENT OF EV3 AND GENERAL UNDERTAKINGS OF EV3.  

        2.1    INVATEC hereby appoints EV3 and EV3 hereby accepts appointment as its exclusive distributor of the  PRODUCTS in the TERRITORY. The PARTIES agree that during
the continuance of the AGREEMENT, INVATEC shall not appoint any other distributor for the distribution
of the PRODUCTS in the TERRITORY, nor distribute or sell the  PRODUCTS in the TERRITORY
directly or through its  AFFILIATES. 

        2.2    INVATEC will retain all distribution rights in the TERRITORY for any
product other than the PRODUCTS. 

        2.3    EV3
undertakes the following obligations vis-à-vis INVATEC: 

	(i)
	EV3
will actively promote, distribute and sell the PRODUCTS in the  TERRITORY to the best of its capability and exercising at least the same level of diligence and efforts it
exercises for the marketing and distribution
of its own PRODUCTS and in accordance with and subject to the terms of this AGREEMENT. EV3 shall not,
either directly or indirectly, and shall cause its AFFILIATES not to, (nor assist any third party in) during the Term of this  AGREEMENT, either directly

3

 

or
indirectly, design, develop, register, launch, market, sell, promote or distribute, in the TERRITORY,  PRODUCTS which are similar in nature to or which in the reasonable
judgment of INVATEC compete with the
PRODUCTS, with the exception of the PRODUCTS which are manufactured and/or sold by EV3 listed in
Exhibit 2; 

	(ii)
	EV3
shall during the continuance of this AGREEMENT diligently and faithfully serve  INVATEC as its distributor in the TERRITORY and
shall use its best endeavours to improve the goodwill of  INVATEC in the TERRITORY and to further increase the sale of the  PRODUCTS in the TERRITORY;

	(iii)
	EV3
will ensure that it conforms to the Laws in force in the TERRITORY in relation to the  PRODUCTS;

	(iv)
	EV3
undertakes to store the PRODUCTS under conditions that will prevent deterioration and also (on the instructions of  INVATEC) to store particular PRODUCTS under such special conditions as may be appropriate to their
requirements. Where EV3 is responsible for clearing goods through customs and other import formalities into the TERRITORY it shall exercise its best
endeavours to ensure that during such clearance the goods are stored as aforesaid. EV3 agrees to allow INVATEC or its authorised representatives to
inspect the PRODUCTS when in storage under the control of EV3 from time to time upon reasonable notice;

	(v)
	EV3
undertakes not to, either directly or indirectly, copy, produce, make, modify or manufacture or assist in any way any other party to copy, produce, make, modify or
manufacture the PRODUCTS or any part thereof for use, sale or any other purpose. 

        2.4    EV3
shall not, and EV3 shall cause its AFFILIATES, not to (i) solicit orders for the sale of  PRODUCTS to any existing or prospective customer outside the TERRITORY, (ii) deliver, tender or
sell (or cause to be delivered, tendered or sold) any Product outside the TERRITORY, or (iii) sell any  PRODUCT to, or solicit any sales from, a customer if EV3
knows or has reason to know that such customer intends to resell the  PRODUCTS outside of the TERRITORY. 

        2.5    Upon
execution of this AGREEMENT EV3 shall pay to INVATEC a sign up fee
of USD 5 million (the "Sign Up Fee") which shall only be recoverable in payment pro rata of 10% of any amount due by EV3 to  INVATEC for PRODUCTS purchased during the Initial Term of this  AGREEMENT. Amounts of the Sign Up Fee not recovered by EV3 during the INITIAL TERM shall
only be payable
to EV3 by INVATECin case of (i) termination of this AGREEMENT for default of  INVATEC; or (ii) no registration of any of
the PRODUCTS is obtained; within two (2) years
from the Effective Date or all of the REGISTRATIONS obtained are cancelled by FDA or any other competent authority, provided that failure in obtaining
the REGISTRATIONS or the cancellation of the REGISTRATIONS, as the case may be, are not attributable to
EV3. 

4

 

ARTICLE 3. CLINICAL TESTS AND REGISTRATIONS.  

        3.1    EV3
undertakes to carry out at its own expense all CLINICAL TESTS and all studies necessary for marketing purposes. 

        3.2    EV3
shall, pursuant to the Laws, apply to FDA and/or to any further competent authority in the TERRITORY for the  REGISTRATION on behalf of and under the name of INVATEC, provided that  INVATEC has presented proper documentation for such application. 

        For
the purpose of obtaining the REGISTRATION of the PRODUCTS,  INVATEC will provide EV3 with all the INFORMATION, documentation and assistance needed in relation to
the REGISTRATION process. 

        Within
thirty (30) days from receipt from INVATEC of the INFORMATION and
documentation needed for the REGISTRATION, EV3 shall submit to the FDA and/or any other competent authority in the  TERRITORY any applications aimed at obtaining the
REGISTRATION of the  PRODUCTS in the TERRITORY.
 

        3.3    Until
the REGISTRATION is granted, EV3 will maintain the overall responsibility for the  REGISTRATION process and will be the leading interface with the regulatory authorities.
It is also agreed that  INVATEC and EV3 will co-operate and support each other on technical and regulatory issues and that EV3 will keep  INVATEC constantly informed on
the relevant REGISTRATION activities.  INVATECwill retain in any event the ultimate control of any strategic decision regarding the PRODUCT
REGISTRATION strategy. 

        3.4    EV3
shall notify INVATEC within one (1) days of any technical complaints that EV3 received from FDA or any other
competent authority, in sufficient detail to allow INVATEC to comply with any and all applicable Laws. EV3 shall also advise  INVATEC of any regulatory action (e.g.
request of INFORMATION on the  PRODUCTS, proposed changes in labelling, packaging, storage conditions, and recalls) which would affect the  PRODUCTS in the TERRITORY. 

        3.5    INVATEC will provide EV3 with the INFORMATION required by any competent
authority for the successful outcome of the REGISTRATION process. EV3 acknowledges that INVATEC has
exclusive ownership title to the INFORMATION. INVATEC grants to EV3, for the Term of the  AGREEMENT, free of charge, the right to
use and cite the INFORMATION for the purpose of the successful
outcome of the REGISTRATION process. EV3 shall identify INVATEC as the owner of all  INFORMATION filed in connection with the
aforementioned REGISTRATION. 

        3.6    EV3
shall not make any changes to the INFORMATION without the prior written consent of  INVATEC. EV3 shall not make any statement and representation in its promotional
materials or otherwise with respect to the  PRODUCTS that are inconsistent with the INFORMATION. 

        3.7    All
relevant costs, including without limitation expenses, levies, fees, charges, for all CLINICAL TESTS and for the  REGISTRATION of the PRODUCTS will be borne by EV3. In the event of early termination of the  AGREEMENT due to the infringement by 

5

 

INVATEC of the obligations provided for by the AGREEMENT,  INVATEC undertakes to reimburse to EV3 the amount of the expenses (with the
exception of internal expenses, e.g. own personnel cost, etc.) incurred for
performing the CLINICAL TESTS that were strictly requested for obtaining from FDA and/or any other competent authority in the  TERRITORY the REGISTRATION of the PRODUCTS, which
exceeds the amount of the aggregate GROSS-PROFIT earned by EV3 by selling the PRODUCTS by the date the
termination becomes effective. 

        3.8    All
experimental protocols, studies and documents that EV3 intends to submit to FDA and/or any other competent authority for the purpose of obtaining any necessary  REGISTRATION for the PRODUCTS shall have to be approved in writing in advance by  INVATECbefore submittal. 

        3.9    The
PARTIES shall keep each other informed in advance of any scheduled meetings or discussions with FDA and/or any other
competent authority in the TERRITORY that involve the safety profile of PRODUCTS. 

        3.10    The
parties recognize that new market requirements may emerge upon the introduction of any of the PRODUCTS into the U.S.
market, or after such introduction, that may require some alterations to the PRODUCT(S) and in such cases, the parties agree to discuss in good faith
the appropriate action(s) needed to ensure market acceptance, and to renegotiate in good faith any terms of the AGREEMENTthat a reasonable business
person would believe should be modified as a result of such market issues. Failure of INVATEC to implement the necessary corrective action, shall give
EV3 the right to terminate the AGREEMENT on 180 days notice, and in such case EV3 shall not be liable to  INVATEC for any penalties or damages under this
AGREEMENT, and  INVATEC shall refund to EV3 any balance not yet credited for the Sign-Up Fee, as well as all external costs incurred in designing and
conducting CLINICAL TESTS with the limits identified in art. 3.7 above. 

ARTICLE 4. TRADEMARKS, LABELS AND OTHER INTELLECTUAL PROPERTY.  

        4.1    All  TRADEMARKS are the exclusive property of INVATEC. 

        4.2    During
the Term of this AGREEMENT, and subject to the terms and conditions herein,  INVATEC hereby grants to EV3 an exclusive, royalty free, non transferable, licence to use the
TRADEMARKS
on the PRODUCTS for relevant distribution in the TERRITORY. Such licence will expire automatically,
without any prior written notice from INVATEC, upon the termination or expiration of the AGREEMENT for
any reason. 

        4.3    The
TRADEMARKS shall not be used in any manner liable to invalidate the registration thereof and the right to use the  TRADEMARKS in connection with the appropriate
PRODUCTS is only granted to the extent that  INVATEC is able to do so without endangering the validity of the registration. 

        4.4    EV3
undertakes not to apply the TRADEMARKS to any item which is not one of the  PRODUCTS nor to distribute or sell any such items with the TRADEMARKS so applied or to engage in any
other practice or activity likely to mislead potential purchasers into believing that an item is one of the PRODUCTS when in fact it is not. 

6

 

        4.5    All  PRODUCTS shall be sold under the co-brand of both INVATEC
and EV3, provided that the co-brand includes with the same prominence the logo and any detail of both the PARTIES. 

        4.6    On
all PRODUCTS, containers, advertisements and technical literature for the  PRODUCTS the symbol ® shall be used in conjunction with the registered TRADEMARKS or "TM" in
conjunction with any Trade Mark applications. All representations of the TRADEMARKS which EV3 intends to use shall first be submitted to  INVATEC for approval in writing.

        4.7    EV3
undertakes to send INVATEC prior to the use of any TRADEMARKS or
brand names a sample of each letter-head, invoice, price-list, label, brochure and all other advertising material displaying such  TRADEMARKS or trade or brand name and only to use items of such printed
materials the proofs for which have received in each case the express and
specific prior approval of INVATEC. 

        4.8    Each
parry shall promptly give notice in writing to the other in the event that it becomes aware of: 

	(i)
	any
infringement or suspected infringement by any third party within the TERRITORY of the  TRADEMARKS, any patent or patent application, or any other intellectual property
rights of INVATEC in or
relating to the PRODUCTS; and

	(ii)
	any
claim or alleged claim that the PRODUCTS sold by EV3 hereunder or that the  TRADEMARKS or trade names or know-how, packaging features or leaflets used by EV3 on or in
connection with the  PRODUCTS, or any patent or patent application under which the PRODUCTS are manufactured, used or sold,
infringes any intellectual property rights of any third party or constitutes an act of unfair competition or parasitism, or any action commenced by a third party in which the declaration of invalidity
of any TRADEMARK and/or any patent application under which the PRODUCTS are manufactured, used or sold,
is sought, which affect or may affect INVATEC's and/or EV3's interests. 

        4.9    INVATEC shall have the right, in its sole discretion, to bring, defend, control and/or direct, in its own name, any legal
proceeding, or other action, including any settlement or negotiation, with respect to the matters described in this Article 4 involving its interests for its own benefit. EV3 shall provide  INVATEC with
any reasonable support and INFORMATION as  INVATEC may request in relation to any such legal proceeding, settlement or negotiation. 

        4.10    At
the request of INVATEC, EV3 shall take part in or give assistance in respect of any legal proceedings and execute any
document and do any things reasonably necessary to protect INVATEC's intellectual and industrial property rights (including without limitation the  TRADEMARKS) in the
TERRITORY. Any relevant cost and expense, including legal fees, related to EV3's
assistance will be sustained by EV3. 

        4.11    The
PARTIES agree to consult each other upon request but, in general, not less frequently than annually, on the need for
changes in labelling of the product INFORMATION supplied to end users, the medical professional or patients. 

7

 

        4.12    EV3
undertakes that following expiration and/or termination for any reason of the AGREEMENT, it will have no further
rights to use and will refrain from further use of TRADEMARKS or of any designs or packaging typical of  PRODUCTS. 

        EV3
undertakes as well that, in any case of expiration and/or termination may occur, it will not use any marks which are so similar to  TRADEMARKS in respect of appearance or meaning that confusion could arise in
practice. 

        4.13    EV3
agrees to take on the responsibility and cost of securing clearance opinions as EV3 in its sole discretion deems to be advisable for introduction and sale of any
and all PRODUCT(S) in the TERRITORY, provided however, that in the event EV3 is unable to secure a
satisfactory clearance opinion upon which it can reasonably rely for any PRODUCT, EV3 may decide in its sole discretion that it will not introduce that
affected PRODUCT, and the parties will reduce the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES and the  MINIMUM ANNUAL VOLUME OF PURCHASES accordingly, provided that should the number of PRODUCTS or the  AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASESbe, as a result of this decision not to introduce the
affected  PRODUCT(S), reduced by at least 2/3, INVATEC shall have the right to terminate this  AGREEMENT upon 6 month notice
in writing. 

ARTICLE 5. ORDERS, DELIVERY AND PAYMENTS.  

        5.1    INVATEC shall supply EV3 with the PRODUCTS. EV3 shall purchase the  PRODUCTS exclusively from INVATEC,
or its AFFILIATES,
designated by INVATEC and shall not, under any circumstances, purchase any product which is similar in nature to or which competes with the  PRODUCTS from any company
other than INVATEC or its  AFFILIATES. 

        5.2    Orders
shall be in writing, or if made verbally have to be confirmed in writing by EV3 within forty-eight (48) hours. Otherwise verbally made orders will be
considered as not placed by EV3. Under no circumstances, an order shall bind INVATEC unless it is accepted in writing by  INVATEC. Notwithstanding the above, it is agreed
that orders which are not rejected by INVATEC within
five (5) Italian business days from the receipt will be deemed to have been accepted by INVATEC. 

        Orders
shall be for delivery in not less than sixty (60) days. 

        5.3    INVATEC reserves the right to reject in whole or in part the ROLLING
FORECASTS pursuant to Article 12.2 below and/or any order without any liability to EV3. It is agreed however that INVATEC
may not reject ROLLING FORECASTS and orders which do not exceed the ANNUAL TARGETS and that comply with
the provisions of Article 12.2 below and that INVATEC may reject orders only for justifiable business reasons (including insufficient production
capacity and overstock by EV3). 

        5.4    In
case of any discrepancy between the order and INVATEC's order confirmation, the latter will prevail, unless EV3
contests it in writing within forty eight (48) hours upon receipt of order confirmation. 

8

 

        5.5    PRODUCTS will be delivered to EV3 Ex Works INVATEC's premises in
Roncadelle (Brescia), Italy (as defined in INCOTERMS 2000) where delivery shall take place. INVATEC
shall give EV3 notice of the date on which the PRODUCTS are to be delivered. All dates for delivery of the  PRODUCTS are given by INVATEC in good faith but are only estimates and  INVATEC shall not be liable for any failure to deliver on the date so given. Collection and transport of the  PRODUCTS
shall be effected by EV3 on its own
responsibility and its own expense. All risks shall pass to EV3 on the date of the delivery of the PRODUCTS under the terms of this Article. 

        5.6    Subject
to Article 5.7 below, unless otherwise agreed upon between the PARTIES in writing, during the first three
contractual years, purchases by EV3 from INVATEC and sales by INVATEC to EV3 shall be made on the basis
of the price-list (hereinafter, the "PRICE-LIST") agreed by the PARTIES per
group of PRODUCTS and attached hereto as Exhibit 3. 

        All
prices for the purchase of the PRODUCTS will be in Euro. It is understood that payments shall remain in Euros throughout the term of
the AGREEMENT, unless the Euro ceases to be the primary legal tender in Europe, in which case the payments under this  AGREEMENT will be made in the new primary European
currency. 

        5.7    Not
later than one hundred and twenty (120) days before the expiration of the INITIAL TERM or of any  RENEWED TERM of the AGREEMENT the PARTIES shall meet for
negotiating in good faith the new PRICE-LIST applicable to the following contractual periods. 

        Should
the PARTIES fail to agree on the new PRICE-LIST not later than ninety
(90) days before the expiration of the AGREEMENT, INVATEC has the right to immediately terminate
the AGREEMENT upon written notice of termination to EV3. Otherwise, the PRICE-LIST in force
at the expiring date will be applied to the RENEWED TERM as increased by 10 (ten) per cent. 

        5.8    The
prices are given in Euro, for delivery Ex Works (as defined in INCOTERMS 2000). The term "unit price" in the  PRICE-LIST means the price for one item. 

        5.9    Unless
otherwise agreed upon in writing, all payments of EV3 to INVATEC shall be made within thirty (30) days from
the date of invoice. Late payments shall bear an interest calculated at 15% per annum. Late payment shall entitle INVATEC to cancel orders, although
confirmed. The right of EV3 to retain payment in total or in part and/or to set-off against any claims shall be excluded. 

ARTICLE 6. MINIMUM ANNUAL, VOLUME OF PURCHASES, ANNUAL TARGETS AND MINIMUM EV3 STAFF.  

        6.1    Subject
to Section 4.13 above, during the TERM of this AGREEMENT,
EV3 undertakes and guarantees to INVATEC to achieve the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES and
the MINIMUM
ANNUAL VOLUME OF PURCHASES agreed upon by the PARTIES as to any and all groups of  PRODUCTS as indicated in Exhibit 4 (in relation with the
INITIAL TERM) as possibly modified from
time to time by AGREEMENTof both PARTIES. 

9

 

        6.2    EV3
shall use its best endeavours to achieve the ANNUAL TARGETS agreed by the  PARTIES and indicated in Exhibit 5. Should EV3 fail to achieve the ANNUAL TARGETS in any year of
the Term of this AGREEMENT, INVATEC may increase the prices of the  PRODUCTS pursuant to the PRICE
LIST by 5% upon notice in writing to EV3. 

        6.3    It
is agreed that the obligations set hereinabove under Articles 6.1 and 6.2 will become effective from the date of first approval for one or more of the  PRODUCTS (the "FIRST APPROVAL
DATE"). 

        6.4    Not
later than one hundred and eighty (180) days prior the expiration of the AGREEMENT the  PARTIES shall meet for negotiating the MINIMUM ANNUAL
VOLUME OF PURCHASES and the  ANNUAL TARGETS to be reached by EV3 over the following contractual years. Should the PARTIES be unable
to find an AGREEMENT on the MINIMUM ANNUAL VOLUME OF PURCHASES and the ANNUAL
TARGETS not later than one hundred and twenty (120) days before the expiration of the AGREEMENT,  INVATEC shall have the right to terminate the
AGREEMENT upon ninety (90) days written notice to
be sent to EV3 within the following thirty (30) days. Otherwise, the MINIMUM ANNUAL VOLUME OF PURCHASES and the ANNUAL
TARGETS in force on the expiring date will be applied to the RENEWED TERM as increased by 20 (twenty) per cent. 

        6.5    For
the purpose of distributing the PRODUCTS in the TERRITORY and
achieving the MINIMUM ANNUAL VOLUME OF PURCHASES and the ANNUAL TARGETS, EV3 undertakes to employ and
maintain employed during the continuance of the AGREEMENT a minimum staff of sales representatives (hereinafter, the Minimum EV3 Staff) in the
activities of promoting, distributing and selling the PRODUCTS in the TERRITORY. The  PARTIES agree that for the purposes of
complying with the minimum staff obligation EV3 shall: 

	(i)
	employ
at least n. [***] sales representatives by the end of January 2005 and maintain them employed till the end of January 2006;

	(ii)
	employ
at least n. [***] sales representatives by the end of January 2006 and maintain them employed during the continuance of the  AGREEMENT. 

        6.6    It
is agreed that the sales representatives employed by EV3 as the Minimum EV3 Staff may also promote and sell EV3  PRODUCTS. 

        6.7    Within
the end of January of any year, EV3 will provide INVATEC with the list of the sales representatives composing the
Minimum EV3 Staff. The PARTIES agree that the list of the sales representatives composing the Minimum EV3 Staff is to be considered confidential and
will be subject to the confidentiality regime set under Article 13.3 and 13.4 hereunder. INVATEC undertakes that for a period of one
(1) year after the expiration/termination of the AGREEMENT it will not solicit and effect the hiring of more than 30% of the sales
representatives employed by EV3 as the Minimum EV3 Staff during the last year of effectiveness of the AGREEMENT. 

[***]
Confidential treatment has been requested for the bracketed portions. The confidential redacted portion has been omitted and filed separately with the Securities and
Exchange Commission. 

10

 

ARTICLE 7. SPECIFICATIONS.  

        7.1    INVATEC warrants to EV3 that the PRODUCTS sold hereunder will meet the
specifications which are set out in Exhibit 6 (the "SPECIFICATIONS"). Any claim concerning the non-compliance of the  PRODUCTS with the SPECIFICATIONS, shall be raised by EV3 within ninety (90) days of the sale of
the PRODUCTS by EV3 to customers. 

        7.2    In
the event of any breach of this warranty, EV3 shall have the exclusive right to require INVATEC, within the
abovementioned term, to replace the defective PRODUCTS at INVATEC's full cost with no right of EV3 of
claiming from INVATEC any further damages of any nature. 

ARTICLE 8. LIABILITIES.  

        8.1    EV3
shall bear full liability for the promotion, distribution and sale of the PRODUCTS in the  TERRITORY and for its other activities related hereto, as well as for complying
with the Laws relating to the  REGISTRATION, import, handling, and/or use of the PRODUCTS in the  TERRITORY. 

        8.2    INVATEC shall not be responsible for any damages, claims or losses that EV3 or third parties may suffer by reason of the
activities mentioned in Article 8.1 or by reason of acts, omissions or negligence on the part of EV3 or its employees or agents with regard to such activities and EV3 shall indemnify and hold  INVATEC
harmless from and against any and all claims, causes of action, demands, losses, liabilities, fines, penalties, costs or expenses of any kind,
including without limitation, reasonable attorney and consultant fees and expenses (hereinafter, collectively "LOSSES"), which may arise out of or be
attributable to EV3's activities or to acts, omissions or negligence of any EV3's employees or agents with regard to such activities. 

        8.3    In
any event, in case of claims, included without limitation claims for infringement of TRADEMARKS or patents in tort and
product liability and whatsoever, arising, connected and/or related to the manufacturing, placement on the market, distribution, use, sale and/or other disposal of any Product in the  TERRITORY, lodged by any
third party against INVATEC and/or EV3, EV3 undertakes to: 

	(i)
	if
so requested by INVATEC, arrange and/or cooperate for the preparation of  INVATEC's defense in the relevant proceedings;

	(ii)
	if
so requested by INVATEC, participate to the proceedings at its own expenses for the purpose of supporting  INVATEC's defense. 

        8.4    [***]

        8.5    [***]

[***]
Confidential treatment has been requested for the bracketed portions. The confidential redacted portion has been omitted and filed separately with the Securities and
Exchange Commission. 

11

 

        8.6    [***]

ARTICLE 9. REPORTING OF ADVERSE EVENTS, RECALLS AND INSURANCE.  

        9.1    EV3
will notify INVATEC within one (1) day of any adverse events related and/or connected to the promotion,
distribution and/or sale of the PRODUCTS in the TERRITORY which come to EV3's or any EV3's
representative notice and will take any temporary appropriate action to protect INVATEC's interests. 

        9.2    In
the event that FDA and/or any other competent authority in the TERRITORY order a recall or take any other action in
connection with the PRODUCTS, EV3 shall notify INVATEC with accurate and detailed  INFORMATION within one (1) day. The
PARTIES will agree on an appropriate course of action to be
taken in the circumstances, provided that any ultimate decision will be the responsibility of INVATEC. Should EV3 not comply with the instructions of
recall provided by INVATEC nor be available to agree with INVATEC the course of action to be taken and
provided that INVATEC's instructions are not in contrast with the laws nor with the regulations and/or requirements of the FDA or any other competent
authority in the TERRITORY, EV3 will solely be liable for any damages suffered or to be suffered which may be claimed by any third party in relation to
the distribution and/or sale of the PRODUCTS and in any event it will indemnify and hold INVATEC
harmless from and against any losses which INVATEC may incur. In the event any governmental or other regulatory 

[***]
Confidential treatment has been requested for the bracketed portions. The confidential redacted portion has been omitted and filed separately with the Securities and
Exchange Commission. 

12

 

body
orders a recall or take guy other action in connection with the PRODUCTS outside the TERRITORY,  INVATEC shall notify EV3 of such
action within three (3) working days, such notification to include a description and reasons for the action
ordered or taken. 

        9.3    EV3
shall take out a suitable insurance policy with a leading insurance company to cover product liability. The policy shall also indicate  INVATEC as the insured party. The sum insured shall not be less than
$2,000,000 and $5,000,000 for a single person and the aggregate per incident,
respectively. EV3 shall send a copy of the policy to INVATEC together with a copy of the documents relating to payment of the premium instalments. 

ARTICLE 10. OBLIGATIONS OF THE PARTIES.  

        10.1    EV3
undertakes to: 

	(i)
	create
and maintain at all times during the term of this AGREEMENT a stock of the  PRODUCTS adequate to meet the demand of customers in the TERRITORY for at least three (3) months;

	(ii)
	carry
out its duties and obligations as distributor and to sell the PRODUCTS in a manner which shall not violate
relevant applicable Laws, particularly those related to marketing of medical devices and to the communication of scientific INFORMATION to medical
professionals;

	(iii)
	give
access to INVATEC to its premises at any time during business hours to inspect the stock of the  PRODUCTS upon three (3) days notice;

	(iv)
	submit
to INVATEC for INVATEC's prior approval, the concept of the
brochures and marketing materials related to the PRODUCTS, provided however that such approval shall be deemed granted if  INVATEC raises no objection within fifteen
(15) days of receipt thereof. Such approval may only be withheld due to scientific, technical,
clinical and regulatory reasons or other reasons of similar importance;

	(v)
	inform
in advance INVATEC of any distribution, partnership, joint venture and any other commercial  AGREEMENT which it intends to enter into and which may concern and/or relate
to PRODUCTS similar in
nature and/or competing with the PRODUCTS.

	(vi)
	abstain
from entering into any of the AGREEMENTs listed in point (v) above in case  INVATEC determines in its reasonable discretion that the result of these AGREEMENTs would be EV3
cooperating in the sale manufacturing or design of PRODUCTS competing with the PRODUCTS. 

        10.2    INVATEC undertakes to: 

	(i)
	carry
out its duties and obligations and to sell the PRODUCTS to EV3 in a manner which shall not violate relevant
applicable laws or regulations; 

13

 

	(ii)
	co-operate
and support EV3 in its distribution activities in the TERRITORY and provide EV3 with all the  INFORMATION, including scientific INFORMATION, needed to promote and sell the  PRODUCTS in the TERRITORY;

	(iii)
	create
and maintain at all times during the term of this AGREEMENT a stock of the  PRODUCTS adequate to meet the demand of EV3 as expressed in the forecasts mentioned in
Article 12.2. 

ARTICLE 11. TERM OF AGREEMENT.  

        11.1    The
AGREEMENT shall come into force at the Effective Date and shall expire after three years from the First Approval
Date (the "INITIAL TERM"). At the end of the INITIAL TERM the  AGREEMENT shall be automatically renewed for a successive period of
two years (the FIRST RENEWED TERM)
provided that EV3 has met the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES and the MINIMUM ANNUAL VOLUME OF
PURCHASES in relation with at least 66% of all the groups of PRODUCTS in the course of any and all contractual years. 

        At
the end of the FIRST RENEWED TERM the AGREEMENT shall be automatically renewed for
successive periods of two (2) years each (the SUCCESSIVE RENEWED TERMS) provided that: 

	(i)
	neither
party serves a written notice of non renewal to the other at least twelve (12) months prior to the expiring date; and

	(ii)
	EV'3
has met the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES and the MINIMUM ANNUAL VOLUME OF
PURCHASES in relation with at least 66% of all the groups of PRODUCTS during the course of any and all years of the relevant  RENEWED TERM.

        11.2    The
provisions contained in Article 13 (CONFIDENTIALITY) and Article 16
(OBLIGATIONS OF EV3 UPON TERMINATION OF THE AGREEMENT) will survive the termination or the expiry of the  AGREEMENT. 

ARTICLE 12. REPORTS.  

        12.1    EV3
agrees to submit to INVATEC once per quarter, INFORMATION regarding
sales and inventory of the PRODUCTS as well as its sales activities in the TERRITORY. EV3 also agrees
(i) to submit in the beginning of the 4th quarter of each calendar year INFORMATION on the sales and marketing of the  PRODUCTS in the TERRITORY during the preceding contractual year; and (ii) to promptly notify
INVATEC in writing of changes in Laws in the TERRITORY which may affect the import, marketing and/or
sale of the PRODUCTS in the TERRITORY. 

        12.2    In
order to enable INVATEC to plan its supply of PRODUCTS to EV3, by the
end of each quarter EV3 shall provide INVATEC with a quarterly rolling twelve (12) months forecast (the "ROLLING
FORECAST") of its purchase requirements for the PRODUCTS, split on a quarterly basis. Once approved by  INVATEC pursuant to Article 5.3 above the
ROLLING FORECAST shall be binding as to quantities
expressed for the incoming quarter and subject to review by EV3 on a quarterly basis provided that 

14

 

quantities
expressed in the revised ROLLING FORECASTS shall not be adjusted by EV3 in excess of: 

	(i)
	10%
in relation with the following second quarter;

	(ii)
	20%
in relation with the following third quarter, and

	(iii)
	30%
in relation with the following fourth quarter. 

ARTICLE 13. CONFIDENTIALITY.  

        13.1    The
PARTIES agree that all rights to the INFORMATION are reserved to  INVATEC and EV3 shall use the INFORMATION only for the purpose of exploiting its rights and fulfilling
its obligations under this AGREEMENT. 

        13.2    EV3
undertakes to keep confidential and not to disclose to any third party the INFORMATION or any other trade secrets of  INVATEC which might be disclosed to EV3 in
connection with the AGREEMENT, unless  INVATEC's prior written consent has been obtained. 

        The
above confidentiality provisions shall not apply to INFORMATION which: 

	(i)
	was
available to the public at the time of disclosure hereunder, as evidenced by suitable published documents;

	(ii)
	became
of public domain after disclosure hereunder, without any fault of EV3;

	(iii)
	was
probably in EV3's lawful possession prior to the disclosure hereunder and not acquired directly or indirectly from  INVATEC, such prior possession to be evidenced by authenticated documentation;

	(iv)
	was
lawfully received by EV3 after disclosure hereunder from a third party who did not acquire the INFORMATION either
directly or indirectly from INVATEC and has the right to disclose such INFORMATION to EV3.

	(v)
	is
independently developed by EV3 without use of the INFORMATION. 

        13.3    INVATEC undertakes to keep confidential and not to disclose to any third party any confidential  INFORMATION or any other trade secrets of EV3 which might be disclosed to INVATEC in connection with the  AGREEMENT, unless EV3's prior written consent has been obtained. 

        The
above confidentiality provisions shall not apply to INFORMATION which: 

	(i)
	was
available to the public at the time of disclosure hereunder, as evidenced by suitable published documents;

	(ii)
	became
of public domain after disclosure hereunder, without any fault of INVATEC; 

15

 

	(iii)
	was
probably in INVATEC's lawful possession prior to the disclosure hereunder and not acquired directly or indirectly
from EV3, such prior possession to be evidenced by authenticated documentation;

	(iv)
	was
lawfully received by INVATEC after disclosure hereunder from a third party who did not acquire the  INFORMATION either directly or indirectly from EV3 and has the right
to disclose such INFORMATION to  INVATEC.

	(v)
	is
independently developed by INVATEC without use of EV3's confidential or proprietary  INFORMATION

        13.4    The
confidentiality obligations under this Article 13 shall also extend to the content of this AGREEMENT and
shall expressly survive the termination or expiration of the AGREEMENT and remain in effect for five (5) years after said termination or
expiration. 

ARTICLE 14. RIGHT TO EARLY TERMINATION.  

        14.1    Each
PARTY hereto shall have the right, without prejudice to any other rights provided by law, to terminate the  AGREEMENT by giving written notice to the other PARTY if any of the following events occur: 

	(i)
	no
REGISTRATION of any of the PRODUCTS in the  TERRITORY under the Laws is obtained within two (2) years from the Effective Date,
 or is cancelled with regard to import, marketing,
distribution, sale or use of the PRODUCTS in the TERRITORY for any reason;

	(ii)
	any
of the PARTIES become insolvent, is adjudicated bankrupt, applies for judicial or extra-judicial settlement with its
creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or alike) in bankruptcy appointed over its business, property or assets,
or a PARTY becomes the subject of liquidation or dissolution or involuntary bankrupt proceedings or otherwise discontinuous business;

	(iii)
	any
of the PARTIES materially breaches any provision of the AGREEMENT
and to the extent such breach is capable of being cured fails to fully cure such breach within forty-five (45) days of receipt of written notice from the  PARTY asserting the breach. 

        14.2    INVATEC will have the right, without prejudice to any other rights provided by law, to immediately terminate the  AGREEMENTby giving written notice to EV3 if any of the following
events occur; 

	(i)
	any
business entity which is a competitor of INVATEC acquires a shareholding which exceeds 49% of the entire issued
voting share capital in EV3, or in any company which owns or controls EV3. EV3 shall promptly notify INVATEC of any such acquisition prior to the time
of its actual occurrence;

	(ii)
	EV3
fails to achieve the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES or achieves the MINIMUM
ANNUAL VOLUME OF PURCHASES in 

16

 

relation
with less than 66% of the groups of PRODUCTS for any contractual year; 

	(iii)
	EV3
materially breaches any of its obligations under Articles 2.3(i), 2.3(iii), 2.3(v), 2.4, 3.6, 4.4, 4.5, 5.1, 6.5, 8.3, 9.2, 9.3, l0.l(iv), l0.1(v), l0.l(vi), 13.2
and 18. 

        14.3    The
termination of this AGREEMENT by either PARTY pursuant to
Article 14.1 and 14.2 of this Article shall operate, as soon as the other PARTY receives notice of termination. 

        14.4    EV3
shall be entitled to terminate this AGREEMENT upon six (6) month notice in writing to  INVATEC should its Gross Profit reduce any lower than 30% as a result of the
price increase of the  PRODUCTS possibly imposed by INVATEC pursuant to Article 6.2 above, provided that  INVATEC has
received prior notice in writing from EV3 of such GROSS PROFIT reduction and declined to
reduce the price of the PRODUCTS to reinstate such minimum 30% GROSS PROFIT. 

ARTICLE 15. FORCE MAJEURE.  

        15.1    If
any party is unable, wholly or in part, by reason of FORCE MAJEURE to carry out any obligations under this  AGREEMENT, the obligation shall be suspended so far as it is
affected by such Force Majeure during the continuance thereof, but no longer than nine
(9) months. The PARTY concerned shall: 

	(i)
	give
the other PARTY prompt notice of such FORCE MAJEURE with reasonably
full particulars thereof and, insofar as known, the probable extent to which it will be unable to perform or be delayed in performing such obligation;

	(ii)
	use
reasonable diligence to remove such FORCE MAJEURE or its effects as quickly as possible. 

        15.2.    For
the purpose of this section "FORCE MAJEURE" shall mean an act of God, war (declared and undeclared), army
mobilization, blockade, revolution, riot, insurrection, civil commotion, sabotage, lightning, fire, earthquake, storm, flood, drought, explosion, strike or other labour unrest, unavailability or
inability to obtain or delay in availability of necessary materials, equipment or transport, and any other cause whether of the kind specifically enumerated above or otherwise which is not reasonably
within the control of the PARTY affected. If the performance of the AGREEMENT is suspended for reasons
of FORCE MAJEURE for more than nine (9) months, then either PARTY may terminate forthwith
the AGREEMENT by written notice addressed to the other PARTY. In such event, neither  PARTY shall be liable towards the other
PARTY by reason of termination of the  AGREEMENT. 

ARTICLE 16. OBLIGATIONS UPON TERMINATION OF THE AGREEMENT.  

        16.1    Without
prejudice to any other provision of this AGREEMENT applicable in case of termination and/or expiration of the  AGREEMENT, upon termination and/or expiration of the
AGREEMENT for whatever causes EV3 irrevocably
undertakes to immediately: 

17

 

	(i)
	transfer
to INVATEC without any expense for INVATEC all  REGISTRATIONS obtained by EV3 on behalf of INVATEC, provided, however, that if termination occurs during
the INITIAL PERIOD and is due to a breach by INVATEC,  INVATEC, shall reimburse EV3 for external costs and expenses associated
with obtaining the  REGISTRATIONS, including the CLINICAL TESTS within the limits quantified in Article 3.7 above;

	(ii)
	transfer
to INVATEC without any expense for INVATEC all  INFORMATION (including any copies thereof) including all product INFORMATION, documentation concerning
clinical trials and tests carried out by EV3 for the purposes of the AGREEMENT;

	(iii)
	transfer
to INVATEC without any expense for INVATEC all  INFORMATION concerning the customers to whom EV3 sold the PRODUCTS;

	(iv)
	cease
to place orders for the PRODUCTS with INVATEC and to promote and
sell the PRODUCTS in the TERRITORY;

	(v)
	cease
to represent in any manner to whoever that it is the distributor of INVATEC in the  TERRITORY;

	(vi)
	return
and transfer to INVATEC all catalogues, price lists, sales and technical literature, documents, samples and other
materials which may have been provided to EV3 during the Term of the AGREEMENT; 

        16.2.    Should
EV3, notwithstanding the termination/expiration of the AGREEMENT, continue to hold the  REGISTRATIONS and the INFORMATION, as well
as not comply with the above provisions, EV3 shall refrain
from: 

	(i)
	using
the INFORMATION in a manner which might be materially prejudicial to the interests of  INVATEC;

	(ii)
	applying
to obtain an extension of the REGISTRATIONS by mentioning a supplier of the  PRODUCTS other than INVATEC or any Affiliate of
INVATEC;

	(iii)
	designing,
developing, manufacturing, distributing, selling and in any event applying to obtain REGISTRATIONS for  PRODUCTS which are similar in nature or which may compete with the
PRODUCTS, with the only exclusion of
the overlapping PRODUCTS which are manufactured and sold by EV3 listed in Exhibit 2;

	(iv)
	taking
any initiative which might prevent INVATEC from using and/or obtaining its own  REGISTRATIONS for the PRODUCTS in the TERRITORY. 

        16.3    The
obligations provided under this Article 16.2 shall expressly survive the termination or expiration of the  AGREEMENT and remain in effect for five (5) years after said termination or expiration.

        16.4    Upon
and after the effective date of termination or expiration of this AGREEMENT for any cause, EV3 shall deliver to  INVATEC an inventory schedule, 

18

 

schedule
of firm orders and schedule of all standing AGREEMENTs to which EV3 is a party. 

        INVATEC may either 

	(i)
	elect
to repurchase or cause to be repurchased from EV3 all or part of the inventory owned by EV3 on the effective date of termination or expiration and if  INVATEC exercises this option, EV3 agrees to sell to
INVATEC or to the third party which will be
indicated by INVATEC all or part of such inventory provided that the PRODUCTS are of good merchantable
quality with a remaining sterile shelf-life of minimum 18 months at the price which EV3 has disbursed and paid to INVATEC when EV3
purchased such inventory from INVATEC; or

	(ii)
	consent
to EV3 to continue to sell its existing stock of PRODUCTS for a period not exceeding six (6) months after
termination of the AGREEMENT. 

        16.5    In
the event of termination of this AGREEMENT, for any cause, any and all sums owing by EV3 to  INVATEC but not yet paid shall automatically and immediately become payable
upon the date of such termination. 

        16.6    Termination
or expiration of this AGREEMENT shall not entitle EV3 to any compensation or indemnity in respect of such
termination or expiration. The goodwill in connection with the distribution and sale of the PRODUCTS in the  TERRITORY pursuant to this AGREEMENT shall be for the sole and exclusive benefit of  INVATEC. 

ARTICLE 17. LIQUIDATED DAMAGES.  

        17.1    Should
INVATEC terminate the AGREEMENT due to EV3's default to its
contractual obligations pursuant to Articles 14.1(i) and (iii) and 14.2(iii) or as a result of a change of control of EV3 pursuant to Article 14.2(i), EV3 will be obliged
to pay to INVATEC liquidated damages for the amount of USD 15 million upon the date of termination. The  PARTIES acknowledge and agree that such amount institutes a
fair and reasonable estimate of the costs which would be incurred by  INVATEC as a result of the termination of the AGREEMENT for the building up of its own sales force
and
as a result of the sales which would be missed in the period the sales force is built. 

        17.2    Should  INVATEC terminate this AGREEMENT pursuant to
Article 14.2(ii) above, EV3 will be obliged to pay to INVATECliquidated damages for an amount equal to USD 5 million. 

        17.3    Without
prejudice to INVATEC's right to early terminate the AGREEMENT
pursuant to Article 14.2(ii) above, in case of EV3's failure to achieve the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES,  INVATEC will have the option not to
terminate the AGREEMENT and claim from EV3 payment of an
indemnification amount equal to 80% of the difference between the AGGREGATE MINIMUM ANNUAL VALUE OF PURCHASES and the total purchases of  PRODUCTS which have been
actually purchased by EV3 during the relevant contractual year. 

19

 

        17.4    Pursuant
to art. 1462 c.c. and without prejudice to EV3's possible right to recover from INVATEC any amount paid in
relation with this Article 17, EV3 shall be obliged to effect payment pursuant to Article 17 within ten (10) business days from receipt of  INVATEC's written demand terminating this AGREEMENT or claiming the indemnification amounts pursuant to
Article 17.2 above as it is the case notwithstanding any exception or opposition EV3 might have and regardless of EV3 filing any dispute in this respect. 

ARTICLE 18. GOOD BUSINESS PRACTICE.  

        EV3 undertakes and warrants to INVATEC that: 

	(i)
	to
its knowledge, the laws of the TERRITORY and the laws governing this  AGREEMENT do not prohibit the distributor or the principal from entering into this AGREEMENT nor do they
render any provision of this AGREEMENT unlawful;

	(ii)
	EV3
will not (in contravention of the Laws or of the laws governing this AGREEMENT) give or agree to give or offer any
gift, loan, fee, reward, advantage or other valuable consideration of any kind to government official, customer representatives, or any other persons for the purpose of furthering the sale of the  PRODUCTS in
the TERRITORY;

	(iii)
	EV3
has no financial or ownership interest, either directly or indirectly, with either government officials, customer representatives, or any other persons who are in
a position to benefit from or influence or further the sale of the PRODUCTS in the TERRITORY;

	(iv)
	at
any time during the existence of this AGREEMENT EV3 will on request to  INVATEC a written confirmation that the undertakings and warranties in clauses 18(i),
(ii) and (iii), remain unbreached. 

ARTICLE 19. SEVERABILITY.  

        If any part, term or provision of the AGREEMENT shall be found illegal under or in conflict with Italian law, the
validity of the remaining provisions shall not be affected and a substitute clause be negotiated to preserve as near as possible the original intent of the  AGREEMENT. 

ARTICLE 20. NO WAIVER OF RIGHTS.  

        The failure of either PARTY hereto at any time to enforce any of the terms, provisions or conditions of the  AGREEMENT shall not be construed as a waiver of the same or of the right of either PARTY to enforce the
same on any subsequent occasion. 

ARTICLE 21. ENTIRE AGREEMENT.  

        21.1    The
making, execution and delivery of the AGREEMENT by INVATEC and by
EV3 have been induced by no representations, statements, warranties or AGREEMENTS other than those herein
expressed. The AGREEMENT, as executed, constitutes the entire AGREEMENT and understanding on the  PRODUCTS between the
PARTIES hereto, and 

20

 

except
as specifically set forth herein there are no AGREEMENTs, understandings, representations, covenants, warranties or guaranties, written or oral,
between the PARTIES, relating to the subject matter of the AGREEMENT. Prior arrangements,  AGREEMENTs and understandings, if any,
are superseded by this AGREEMENT. 

        21.2    It
is further understood and agreed that the AGREEMENT may only be amended, modified or supplemented by a written
instrument executed by both PARTIES. The PARTIES remedies with respect to the  AGREEMENT, whether in contract or otherwise, shall
be limited to those expressly set forth in the  AGREEMENT. 

ARTICLE 22. INTERPRETATION OF THE AGREEMENT.  

        22.1    Except
as otherwise expressly set forth in this AGREEMENT in order to fulfil the obligation here undertaken in reference
to the PRODUCTS, none of the provision of this AGREEMENT shall be construed as granting EV3 any license
expressed or implied to use in any manner the TRADEMARKS and or any trade name, patents, know-how, packaging or packaging leaflets covering
the PRODUCTS and of which INVATEC is or may become the owner or has or will have the right to use and
which relate or will relate to the PRODUCTS. 

        22.2    In
order to avoid any doubt and notwithstanding the provision contained in this AGREEMENT, the  PARTIES hereby declare that nothing in this AGREEMENT shall be construed as granting EV3 any right
whatsoever to manufacture the PRODUCTS. 

        22.3    Nothing
in this AGREEMENT shall create a partnership or joint venture between the  PARTIES hereto and save as expressly provided in this AGREEMENT neither  PARTY shall enter into or have authority to enter into any engagement or make any representation or warranty on behalf of or otherwise bind or oblige
the other PARTY hereto. 

ARTICLE 23. ASSIGNMENT.  

        Neither PARTY shall, without the prior written consent of the other  PARTY, assign the AGREEMENT or any of the rights hereunder, nor delegate any of the duties or
obligations hereunder provided however that INVATEC may at any time assign to any third parties the credits deriving to it from the  AGREEMENT. 

        Any
assignment or delegation in derogation of this provision shall be deemed null or void. 

ARTICLE 24. NOTICES.  

        All notices to be effective hereunder must be by registered mail, by Federal Express or by fax in writing and, if they are meant for  INVATEC,
addressed to: 

	INVATEC S.r.l.	 	Via Martiri della Liberta, 7

25030 Roncadelle (BS)

Italy

21

 

	 	 	Attn.:	Andrea Venturelli CEO
	 	 	Tel:	+39 030 2589331
	 	 	Fax	+39 030 2589349
	

and, if they are meant for EV3,

addressed to:	
 	

4600 Nathan Lane North

Plymouth, Minnesota 55442
	

 	
 	

Attn.:	

James M. Corbett
	

With a copy to:	
 	

Ms. Cecily Hines, Chief Legal Officer

(at the same address)
	

 	
 	

Tel:	

[•]
	 	 	Fax:	[•]

provided
also that each PARTY shall promptly notify the other by registered mail of any change of address. 

ARTICLE 25. GOVERNING LAW.  

        The AGREEMENT shall be governed by and construed and enforced in accordance with the Italian substantive Law and
shall bind INVATEC and EV3 as well as their successors in any country of the world. 

ARTICLE 26. ARBITRATION.  

        The PARTIES shall use their best efforts to amicably settle any dispute which may arise between them in connection
with the AGREEMENT. 

        Failing
an amicable settlement, all disputes under this AGREEMENT shall be submitted to Arbitration according to the Arbitration Rules of
the German Institution of Arbitration e.V. (DIS) without recourse to the ordinary courts of law. The arbitral tribunal shall consist of three arbitrators. The place of arbitration shall be Frankfurt
am Main, Germany and the language of the arbitration shall be English. 

	INVATEC S.R.L.	 	EV3 INC.
	

 	
 	

 
	/s/  ANDREA VENTURELLI      
 Andrea Venturelli

President & C.E.O

30/06/2004	 	/s/  JAMES M. CORBETT      
 James M. Corbett

President, CEO

22

QuickLinks

Exhibit 10.34

DISTRIBUTION AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]